Autres langues Catalyst Biosciences

Actions

CBIO

US14888D2080

Marché Fermé - Nasdaq 22:00:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
6,650 ^USD	-0,45%		-4,30%	-13,29%

16/06/25	Crescent Biopharma finalise sa fusion avec GlycoMimetics	MT
30/10/23	Beijing Continent Pharmaceutical Co. a finalisé l'acquisition de Catalyst Biosciences, Inc. (NasdaqCM:CBIO) dans le cadre d'une opération de fusion inversée.	CI

Autres langues

16/06/25	Crescent Biopharma Completes Merger With GlycoMimetics
11/05/24	Catalyst Biosciences : Investor presentation 556.6 KB
09/05/24	Catalyst Biosciences : Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K
08/05/24	Catalyst Biosciences : Notification of Conclusion of License Agreement by Gyre Pharmaceuticals Co - Form 8-K
03/05/24	Catalyst Biosciences : Investor presentation 556.8 KB
02/05/24	Catalyst Biosciences : Investor presentation 556.2 KB
06/12/23	Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K
06/11/23	Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K
02/11/23	Catalyst Biosciences : Change in Certifying Accountants - Form 8-K
30/10/23	Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
30/10/23	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index
30/10/23	Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.
30/10/23	Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.
27/10/23	Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.
26/10/23	Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
29/08/23	Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc
14/08/23	Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
25/07/23	Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders
22/07/23	CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
15/05/23	Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
05/05/23	CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
07/04/23	CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
30/03/23	CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
30/03/23	CATALYST BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
30/03/23	Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022